Advertisement
CRON vs TRLV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRON is a Hold and TRLV is a Hold.
CRON in downward trend: price may decline as a result of having broken its higher Bollinger Band on September 22, 2026
CRON broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 44 similar instances where the stock broke above the upper band. In 41 of the 44 cases the stock fell afterwards. This puts the odds of success at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRON as a result. In 81 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for CRON turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 58 similar instances when the indicator turned negative. In 45 of the 58 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
CRON moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRON crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in 168 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.107) is normal, around the industry mean (43.873). P/E Ratio (16.895) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (6.993) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
TRLV sees MACD Histogram crosses below signal line
TRLV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 34 instances where the indicator turned negative. In 31 of the 34 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRLV as a result. In 72 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
TRLV moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TRLV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in 190 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 113 of 140 cases where TRLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.512) is normal, around the industry mean (43.873). P/E Ratio (-4.053) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.470) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.947) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
CRON | TRLV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 47 Fair valued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 80 | 98 | |
PRICE GROWTH RATING 1..100 | 41 | 41 | |
P/E GROWTH RATING 1..100 | 98 | 12 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRON's Valuation (47) in the Pharmaceuticals Other industry is in the same range as TRLV (74) in the null industry. This means that CRON’s stock grew similarly to TRLV’s over the last 12 months.
CRON's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as TRLV (100) in the null industry. This means that CRON’s stock grew similarly to TRLV’s over the last 12 months.
CRON's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as TRLV (98) in the null industry. This means that CRON’s stock grew similarly to TRLV’s over the last 12 months.
CRON's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as TRLV (41) in the null industry. This means that CRON’s stock grew similarly to TRLV’s over the last 12 months.
TRLV's P/E Growth Rating (12) in the null industry is significantly better than the same rating for CRON (98) in the Pharmaceuticals Other industry. This means that TRLV’s stock grew significantly faster than CRON’s over the last 12 months.
| CRON | TRLV | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 76% | 3 days ago 85% |
| Momentum ODDS (%) | 3 days ago 78% | 3 days ago 86% |
| MACD ODDS (%) | 3 days ago 78% | 7 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 77% | 3 days ago 86% |
| TrendMonth ODDS (%) | 3 days ago 76% | 3 days ago 84% |
| Advances ODDS (%) | 3 days ago 74% | 20 days ago 80% |
| Declines ODDS (%) | 5 days ago 76% | 5 days ago 86% |
| BollingerBands ODDS (%) | 3 days ago 90% | N/A |
| Aroon ODDS (%) | N/A | 3 days ago 81% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRON’s FA Score shows that 0 FA rating(s) are green while TRLV’s FA Score has 1 green FA rating(s).
- CRON’s FA Score: 0 green, 5 red.
- TRLV’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRON’s TA Score shows that 2 TA indicator(s) are bullish while TRLV’s TA Score has 3 bullish TA indicator(s).
- CRON’s TA Score: 2 bullish, 6 bearish.
- TRLV’s TA Score: 3 bullish, 5 bearish.
Price Growth
CRON (@Pharmaceuticals: Generic) experienced а -0.62% price change this week, while TRLV (@Pharmaceuticals: Generic) price change was -6.19% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -6.95%. For the same industry, the average monthly price growth was -5.23%, and the average quarterly price growth was +10.96%.
Reported Earning Dates
CRON is expected to report earnings on Nov 05, 2026.
TRLV is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-6.95% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
CRON and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRON has been closely correlated with SNDL. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To CRON | 1D Price Change % | ||
|---|---|---|---|---|
| CRON | 100% | +0.31% | ||
| SNDL - CRON | 73% Closely correlated | +3.31% | ||
| ACB - CRON | 60% Loosely correlated | -2.68% | ||
| CGC - CRON | 60% Loosely correlated | -3.06% | ||
| TLRY - CRON | 59% Loosely correlated | -5.30% | ||
| TRLV - CRON | 55% Loosely correlated | -2.82% | ||
More | ||||
TRLV and
Correlation & Price change
A.I.dvisor indicates that over the last year, TRLV has been closely correlated with GLAS. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if TRLV jumps, then GLAS could also see price increases.
| Ticker / NAME | Correlation To TRLV | 1D Price Change % | ||
|---|---|---|---|---|
| TRLV | 100% | -2.82% | ||
| GLAS - TRLV | 69% Closely correlated | -14.02% | ||
| CGC - TRLV | 67% Closely correlated | -3.06% | ||
| TLRY - TRLV | 58% Loosely correlated | -5.30% | ||
| ACB - TRLV | 56% Loosely correlated | -2.68% | ||
| CRON - TRLV | 55% Loosely correlated | +0.31% | ||
More | ||||